The requested news item does not exist. Please return to News
Singapore, 21 November 2013 – On 15 November, Merck KGaA, a global pharmaceutical, chemical and life science company headquartered in Darmstadt, Germany, announced a EUR 80 million (approximately USD 110 million) investment to establish its pharmaceutical manufacturing facility at the national-level Nantong Economic & Technological Development Area. This will be the second largest pharmaceutical manufacturing site for Merck Serono (the biopharmaceutical division of Merck KGaA) globally.
As the appointed real estate consultant, Jones Lang LaSalle’s Industrial team provided site selection consultancy, government communication and transaction assistance services to Merck KGaA. The new facility will cover a land area of 40,000 sqm, with a possible 20,000 sqm extension. Belén Garijo, President and Chief Executive Officer of Merck Serono, and Zhang Guohua, Mayor of Nantong City, both attended the signing ceremony on 15 November with other VIP guests.
China’s pharmaceutical industry has enjoyed massive growth over the past decade. With the world’s largest population, second largest economy and a growing middle class, China’s prospective consumer base is unmatched by any country worldwide. The country’s emergence onto the radar of multinational life science companies parallels its growth into one of the world’s dominant economies with an increasingly open and inviting marketplace with waves of foreign investors lined up to take part. Merck KGaA’s investment is not only in full alignment with this trend, but also the Chinese government’s goal to increase access to quality medicines.
This latest assignment from Merck KGaA demonstrates Jones Lang LaSalle’s expertise and capabilities in supporting global biopharmaceutical companies in their China expansions, as well as the firm’s strong relationship and cooperation with the municipal governments in attracting investment from leading multinational companies. Jones Lang LaSalle has also helped other pharmaceutical companies on site selection in China. For example, supporting AstraZeneca’s investment of USD 230 million in Taizhou Medical High-Tech Park as announced in 2011, which was AstraZeneca’s largest ever investment in a single manufacturing facility worldwide.
+86 (21) 6133 5390